$10995 | Single User
$21990 | Site License
$32985 | Enterprise License

PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024

Published by Global Data: 01 Mar 2016 | 26558 | In Stock

Introduction

PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024

Summary

Bipolar disorder is a mental disorder characterized by periods of mania and depression. The frequency, severity, and pattern of these episodes can vary considerably over time and between individuals, making bipolar disorder one of the most challenging psychiatric disorders to manage. The bipolar disorder market is widely genericized, with additional key brands expected to face patent or data exclusivity expiries during the forecast period. The bipolar disorder market size is anticipated to contract significantly between 2014 and 2024, driven largely by the generic erosion of Otsuka’s Abilify, the highest selling bipolar disorder product in 2014. The uptake of novel atypical antipsychotic products will be a principal driver of growth over the forecast period, as these products offer clinical advantages that will drive strong uptake. However, sales of these agents will be limited by the continued utilization of established generic products. There are currently only two products in Phase III development, which indicates that bipolar disorder will remain a field of high unmet need during the forecast period.

Highlights

Key Questions Answered

- The bipolar disorder market is heavily genericized and many key players have chosen to deprioritize the indication. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period?

- The current late-stage bipolar disorder pipeline is sparse, with only two products in Phase III development. What impact will these drugs have on the market? How will they affect the treatment algorithm for bipolar disorder? Will these drugs fulfil any of the unmet needs for bipolar disorder?

- The management of bipolar disorder patients is challenging and a large number of variables can impact treatment outcomes. How does the diagnosis and treatment of bipolar disorder differ amongst the 8MM? Which treatment options are most commonly prescribed in each market, and how will prescribing patterns change over the forecast period?

Key Findings

- The main driver of growth in the bipolar disorder market will be the uptake of novel atypical antipsychotic products, such as Otsuka/Lundbeck’s Abilify Maintena and Allergan/Gedeon Richter/Mitsubishi Tanabe’s Vraylar. These agents are forecast to be the highest selling bipolar disorder products by 2024, accounting for 34.9% of the bipolar disorder market in the 8MM.

- There are very few products approved for the treatment of major depressive episodes, despite the fact that patients most commonly experience this episode type. This unmet need is not expected to be addressed during the forecast period due to the sparsity of the late-stage pipeline.

- The biggest barrier for growth in the bipolar disorder market will be fierce competition from generic products. This limits market opportunities for new and existing players, as uptake of novel pipeline products would be hindered by their premium price point.

- Considerable opportunity remains for products with superior safety profiles compared to the currently available drugs. KOLs noted that EPS and metabolic changes were significant concerns related to the antipsychotic drugs.

Scope

- Overview of bipolar disorder, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

- Annualized bipolar disorder market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.

- Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the bipolar disorder therapeutics market.

- Pipeline analysis: focus on two late-stage pipeline bipolar disorder drugs, discussing emerging trends as well as an overview of earlier phase drugs and a top-line analysis of off-label treatments.

- Analysis of the current and future market competition in the global bipolar disorder therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

- Develop business strategies by understanding the trends shaping and driving the global bipolar disorder therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bipolar disorder therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Track drug sales in the global bipolar disorder therapeutics market from 2014-2024.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents
for PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024

  • 1 Table of Contents

    1 Table of Contents 12

    1.1 List of Tables 17

    1.2 List of Figures 24

    2 Introduction 26

    2.1 Catalyst 26

    2.2 Related Reports 27

    2.3 Upcoming Related Reports 27

    3 Disease Overview 28

    3.1 Etiology and Pathophysiology 28

    3.1.1 Etiology 28

    3.1.2 Pathophysiology 30

    3.2 Classification 34

    3.3 Symptoms 40

    3.4 Prognosis 41

    4 Epidemiology 43

    4.1 Disease Background 43

    4.2 Risk Factors and Comorbidities 43

    4.3 Global Trends 45

    4.4 Forecast Methodology 47

    4.4.1 Sources Used 53

    4.4.2 Sources Not Used 56

    4.4.3 Forecast Assumptions and Methods 56

    4.5 Epidemiological Forecast of Bipolar Disorder (2014-2024) 60

    4.5.1 12-Month Total Prevalent Cases of Bipolar Spectrum Disorder 60

    4.5.2 12-Month Total Prevalent Cases of Bipolar I 61

    4.5.3 12-Month Total Prevalent Cases of Bipolar II 63

    4.5.4 12-Month Total Prevalent Cases of Cyclothymic Disorder 65

    4.5.5 Lifetime Total Prevalent Cases of Bipolar Spectrum Disorder 67

    4.5.6 Age-Specific 12-Month Total Prevalent Cases of Bipolar I 68

    4.5.7 Age-Specific 12-Month Total Prevalent Cases of Bipolar II 70

    4.5.8 Age-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder 72

    4.5.9 Sex-Specific 12-Month Total Prevalent Cases of Bipolar I 74

    4.5.10 Sex-Specific 12-Month Total Prevalent Cases of Bipolar II 76

    4.5.11 Sex-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder 78

    4.5.12 Age-Standardized 12-Month Total Prevalence of Bipolar Spectrum Disorder 80

    4.6 Discussion 82

    4.6.1 Epidemiological Forecast Insight 82

    4.6.2 Limitations of the Analysis 83

    4.6.3 Strengths of the Analysis 84

    5 Disease Management 85

    5.1 Diagnosis Overview 85

    5.1.1 Clinical Evaluation 85

    5.1.2 Screening Tools 86

    5.2 Treatment Overview 88

    5.2.1 Treatment Initiation and Maintenance Therapy 88

    5.2.2 Manic or Mixed Episodes 91

    5.2.3 Acute Agitation 93

    5.2.4 Hypomanic Episodes 94

    5.2.5 Major Depressive Episodes 96

    5.2.6 Rapid Cycling 99

    5.2.7 Cyclothymia 101

    5.2.8 Other Treatment Factors 102

    5.3 Treatment Guidelines and Leading Prescribed Drugs 105

    5.4 US 106

    5.5 5EU 110

    5.6 Japan 115

    5.7 Canada 120

    6 Competitive Assessment 125

    6.1 Overview 125

    6.2 Product Profiles - Major Brands 127

    6.2.1 Lithium 127

    6.2.2 Anticonvulsants 136

    6.2.3 Typical Antipsychotics 157

    6.2.4 Atypical Antipsychotics 170

    6.2.5 Antidepressants 261

    6.3 Other Therapeutic Classes 268

    7 Unmet Need and Opportunity 270

    7.1 Overview 270

    7.2 Effective Treatment Options for Bipolar Depression 271

    7.2.1 Unmet Need 271

    7.2.2 Gap Analysis 274

    7.2.3 Opportunity 275

    7.3 Antipsychotics with a Low Risk of EPS and Metabolic Changes 276

    7.3.1 Unmet Need 276

    7.3.2 Gap Analysis 277

    7.3.3 Opportunity 278

    7.4 Mood Stabilizers with Improved Safety Profiles 279

    7.4.1 Unmet Need 279

    7.4.2 Gap Analysis 282

    7.4.3 Opportunity 282

    7.5 Education for Physicians in Order to Improve Diagnosis Rates 284

    7.5.1 Unmet Need 284

    7.5.2 Gap Analysis 286

    7.5.3 Opportunity 286

    7.6 Novel Drugs Developed Specifically for Bipolar Disorder 286

    7.6.1 Unmet Need 286

    7.6.2 Gap Analysis 288

    7.6.3 Opportunity 289

    8 Pipeline Assessment 290

    8.1 Overview 290

    8.1.1 Clinical Trials by Class of Therapy 290

    8.2 Promising Drugs in Clinical Development 292

    8.2.1 Abilify Maintena 293

    8.2.2 ITI-007 303

    8.3 Off-label Pipeline and Recently Approved Therapies 310

    8.4 Promising Drugs in Early-Stage Development 311

    8.5 Other Drugs in Development 312

    9 Current and Future Players 314

    9.1 Overview 314

    9.2 Trends in Corporate Strategy 317

    9.3 Company Profiles 318

    9.3.1 Otsuka 318

    9.3.2 AstraZeneca 322

    9.3.3 Eli Lilly 324

    9.3.4 Allergan 327

    9.3.5 Dainippon Sumitomo 329

    9.3.6 Janssen 332

    9.3.7 Lundbeck 335

    9.3.8 Meiji Seika 338

    10 Market Outlook 341

    10.1 Global Markets 341

    10.1.1 Forecast 341

    10.1.2 Drivers and Barriers - Global Issues 348

    10.2 United States 349

    10.2.1 Forecast 349

    10.2.2 Key Events 354

    10.2.3 Drivers and Barriers 355

    10.3 5EU 356

    10.3.1 Forecast 356

    10.3.2 Key Events 362

    10.3.3 Drivers and Barriers 363

    10.4 Japan 364

    10.4.1 Forecast 364

    10.4.2 Key Events 369

    10.4.3 Drivers and Barriers 370

    10.5 Canada 371

    10.5.1 Forecast 371

    10.5.2 Key Events 376

    10.5.3 Drivers and Barriers 377

    11 Appendix 378

    11.1 Bibliography 378

    11.2 Abbreviations 413

    11.3 Methodology 418

    11.4 Forecasting Methodology 418

    11.4.1 Diagnosed Bipolar Disorder Patients 418

    11.4.2 Percent Drug-Treated Patients 419

    11.4.3 Launch and Patent Expiry Dates 419

    11.4.4 General Pricing Assumptions 420

    11.4.5 Individual Drug Assumptions 421

    11.4.6 Generic Erosion 432

    11.5 Primary Research - KOLs Interviewed for this Report 433

    11.6 Primary Research - Prescriber Survey 436

    11.7 About the Authors 437

    11.7.1 Analyst 437

    11.7.2 Therapy Area Director 437

    11.7.3 Epidemiologist 438

    11.7.4 Global Director of Therapy Research and Analysis 438

    11.8 About GlobalData 439

    11.9 Disclaimer 439

List Of Tables
in PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024

1.1 List of Tables

Table 1: Classification and Criteria of Bipolar Disorder According to DSM-V and ICD-10-CM 37

Table 2: DSM-V Bipolar Disorder Specifiers 39

Table 3: Symptoms of Manic, Hypomanic, and Major Depressive Episodes in Bipolar Disorder 41

Table 4: Risk Factors and Comorbidities for Bipolar Disorder 44

Table 5: 8MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Bipolar Disorder I 48

Table 6: 8MM, Sources Used to Forecast the Lifetime Total Prevalent Cases of Bipolar Disorder I 49

Table 7: 8MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Bipolar Disorder II 50

Table 8: 8MM, Sources Used to Forecast the Lifetime Total Prevalent Cases of Bipolar Disorder II 51

Table 9: 8MM, Sources Used to Forecast 12-Month Total Prevalent Cases of Cyclothymic Disorder 52

Table 10: 8MM, Sources Used to Forecast Lifetime Total Prevalent Cases of Cyclothymic Disorder 52

Table 11: 8MM, 12-Month Total Prevalent Cases of Bipolar Spectrum Disorder Summary, Both Sexes, Ages ≥13 Years, N (Row %), 2014 61

Table 12: 8MM, 12-Month Total Prevalent Cases of Bipolar I, Both Sexes, Ages ≥13 Years, 2014-2024 62

Table 13: 8MM, 12-Month Total Prevalent Cases of Bipolar II, Both Sexes, Ages ≥13 Years, 2014-2024 64

Table 14: 8MM, 12-Month Total Prevalent Cases of Cyclothymic Disorder, Both Sexes, Ages ≥13 Years, 2014-2024 66

Table 15: 8MM, Lifetime Total Prevalent Cases of Bipolar Spectrum Disorder Summary, Both Sexes, Ages ≥13 Years, N (Row %), 2014 68

Table 16: 8MM, Age-Specific 12-Month Total Prevalent Cases of Bipolar I, Both Sexes, Ages ≥13 Years, N (Row %), 2014 69

Table 17: 8MM, Age-Specific 12-Month Total Prevalent Cases of Bipolar II, Both Sexes, Ages ≥13 Years, N (Row %), 2014 71

Table 18: 8MM, Age-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder, Both Sexes, Ages ≥13 Years, N (Row %), 2014 73

Table 19: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Bipolar I, Ages ≥13 Years, N (Row %), 2014 75

Table 20: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Bipolar II, Ages ≥13 Years, N (Row %), 2014 77

Table 21: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder, Ages ≥13 Years, N (Row %), 2014 79

Table 22: Screening Tools Used for Bipolar Disorder 87

Table 23: Treatment Guidelines for Bipolar Disorder 105

Table 24: Most Prescribed Drugs for Bipolar Disorder by Episode Type in the Global Markets, 2014 106

Table 25: Country Profile - US 109

Table 26: Country Profile - 5EU 114

Table 27: Country Profile - Japan 119

Table 28: Country Profile - Canada 123

Table 29: Leading Treatments for Bipolar Disorder, 2015 126

Table 30: Product Profile - Lithium 132

Table 31: Lithium SWOT Analysis, 2015 135

Table 32: Global Sales Forecasts ($m) for Lithium, 2014-2024 136

Table 33: Product Profile - Carbamazepine 139

Table 34: Efficacy Results for Equetro in Bipolar Mania Trials 140

Table 35: Adverse Events at ≥5% Incidence in Bipolar Mania Trials of Equetro 141

Table 36: Carbamazepine SWOT Analysis, 2015 142

Table 37: Global Sales Forecasts ($m) for Carbamazepine, 2014-2024 143

Table 38: Product Profile - Lamotrigine 145

Table 39: Adverse Events at ≥5% Incidence in Bipolar Maintenance Trials of Lamictal 147

Table 40: Lamotrigine SWOT Analysis, 2015 149

Table 41: Global Sales Forecasts ($m) for Lamotrigine, 2014-2024 150

Table 42: Product Profile - Valproate 153

Table 43: Efficacy Results for Depakote in Bipolar Mania Trials 154

Table 44: Adverse Events at ≥5% Incidence in Bipolar Mania Trials of Depakote 155

Table 45: Valproate SWOT Analysis, 2015 156

Table 46: Global Sales Forecasts ($m) for Valproate, 2014-2024 157

Table 47: Typical Antipsychotics by Chemical Class 159

Table 48: Typical antipsychotics SWOT Analysis, 2015 162

Table 49: Global Sales Forecasts ($m) for the Typical Antipsychotics, 2014-2024 163

Table 50: Product Profile - Adasuve 166

Table 51: Efficacy Results for Adasuve in Agitation Trial of Bipolar I Disorder Patients 167

Table 52: Decrease in FEV1 in Pulmonary Safety Trials of Adasuve 168

Table 53: Adasuve SWOT Analysis, 2015 169

Table 54: Global Sales Forecasts ($m) for Adasuve, 2014-2024 170

Table 55: Product Profile - Abilify 174

Table 56: Efficacy Results for Abilify in Bipolar Mania Trials 175

Table 57: Efficacy Results for Abilify in Agitation Trials 177

Table 58: Adverse Events at ≥2% Incidence in Bipolar I Disorder and Schizophrenia Trials of Abilify 178

Table 59: Abilify SWOT Analysis, 2015 180

Table 60: Global Sales Forecasts ($m) for Abilify, 2014-2024 181

Table 61: Product Profile - Geodon 183

Table 62: Adverse Events at ≥2% Incidence in Bipolar Mania Trials of Geodon 186

Table 63: Geodon SWOT Analysis, 2015 187

Table 64: Global Sales Forecasts ($m) for Geodon, 2014-2024 188

Table 65: Product Profile - Latuda 191

Table 66: Efficacy Results for Latuda in Bipolar Depression Trials 192

Table 67: Adverse Events at ≥2% Incidence in Bipolar Depression Trials of Latuda 194

Table 68: Latuda SWOT Analysis, 2015 195

Table 69: Global Sales Forecasts ($m) for Latuda, 2014-2024 196

Table 70: Product Profile - Risperdal 199

Table 71: Efficacy Results for Risperdal in Trial of Manic and Mixed Bipolar Episodes 200

Table 72: Adverse Events at ≥2% Incidence in Bipolar Mania Trials of Risperdal 204

Table 73: Adverse Events at ≥2% Incidence in Bipolar Maintenance Trials of Risperdal Consta 206

Table 74: Risperdal SWOT Analysis, 2015 207

Table 75: Global Sales Forecasts ($m) for Risperdal, 2014-2024 208

Table 76: Global Sales Forecasts ($m) for Risperdal Consta, 2014-2024 209

Table 77: Product Profile - Saphris 212

Table 78: Efficacy Results for Saphris in Bipolar Mania Studies 214

Table 79: Adverse Events at ≥2% Incidence in Bipolar I Disorder Trials of Saphris 217

Table 80: Saphris SWOT Analysis, 2015 218

Table 81: Global Sales Forecasts ($m) for Saphris, 2014-2024 219

Table 82: Product Profile - Seroquel 222

Table 83: Efficacy Results for Seroquel in Bipolar Mania Studies 224

Table 84: Efficacy Results for Seroquel in Bipolar Depression Trials 225

Table 85: Efficacy Results for Seroquel XR in Bipolar Disorder Trials 226

Table 86: Adverse Events at ≥2% Incidence in Bipolar Disorder Trials of Seroquel 228

Table 87: Adverse Events at ≥2% Incidence in Bipolar Disorder Trials of Seroquel XR 230

Table 88: Seroquel SWOT Analysis, 2015 232

Table 89: Global Sales Forecasts ($m) for Seroquel, 2014-2024 233

Table 90: Global Sales Forecasts ($m) for Seroquel XR, 2014-2024 234

Table 91: Product Profile - Symbyax 236

Table 92: Efficacy Results for Symbyax in Bipolar Depression Trials 237

Table 93: Adverse Events at ≥2% Incidence in Bipolar Depression and Treatment-Resistant Depression Trials of Symbyax 239

Table 94: Symbyax SWOT Analysis, 2015 241

Table 95: Global Sales Forecasts ($m) for Symbyax, 2014-2024 242

Table 96: Product Profile - Vraylar 244

Table 97: Vraylar SWOT Analysis, 2015 247

Table 98: Global Sales Forecast ($) for Vraylar, 2014-2024 248

Table 99: Product Profile - Zyprexa 251

Table 100: Adverse Events at ≥2% Incidence in Bipolar Mania Trials of Zyprexa 255

Table 101: Adverse Events at ≥2% Incidence in Trials of Zyprexa IntraMuscular in Agitation Associated with Schizophrenia or Bipolar I Mania 257

Table 102: Zyprexa SWOT Analysis, 2015 258

Table 103: Global Sales Forecasts ($m) for Zyprexa, 2014-2024 259

Table 104: Product Information for the Most Commonly Prescribed “Other Antipsychotics” 260

Table 105: International Society for Bipolar Disorders Clinical Recommendations for Antidepressant Use in Bipolar Disorder 263

Table 106: Antidepressants SWOT Analysis, 2015 267

Table 107: Global Sales Forecasts ($m) for the Antidepressants, 2014-2024 268

Table 108: Summary of Minor Therapeutic Classes, 2015 269

Table 109: Unmet Need and Opportunity in Bipolar Disorder 271

Table 110: Product Profile - Abilify Maintena 296

Table 111: Adverse Events at ≥2% Incidence in a Schizophrenia Trial of Abilify Maintena 299

Table 112: Abilify Maintena SWOT Analysis, 2015 302

Table 113: Global Sales Forecast ($) for Abilify Maintena, 2014-2024 303

Table 114: Product Profile - ITI-007 305

Table 115: Efficacy Results for ITI-007 in a Phase II Schizophrenia Trial 306

Table 116: Key Safety Data From a Phase II in a Schizophrenia Trial of ITI-007 307

Table 117: ITI-007 SWOT Analysis, 2015 310

Table 118: Potential Off-label Bipolar Disorder Late-Stage Pipeline Drugs 311

Table 119: Drugs in Development, 2015 313

Table 120: Key Companies in the Bipolar Disorder Market in the 8MM, 2015 315

Table 121: Otsuka’s Bipolar Disorder Portfolio Assessment, 2015 321

Table 122: AstraZeneca’s Bipolar Disorder Portfolio Assessment, 2015 323

Table 123: Eli Lilly’s Bipolar Disorder Portfolio Assessment, 2015 326

Table 124: Allergan’s Bipolar Disorder Portfolio Assessment, 2015 328

Table 125: Dainippon Sumitomo’s Bipolar Disorder Portfolio Assessment, 2015 331

Table 126: Janssen Bipolar Disorder Portfolio Assessment, 2015 334

Table 127: Lundbeck Bipolar Disorder Portfolio Assessment, 2015 337

Table 128: Meiji Seika Bipolar Disorder Portfolio Assessment, 2015 339

Table 129: Global Sales Forecast ($m) for Bipolar Disorder, 2014-2024 344

Table 130: Bipolar Disorder Market - Drivers and Barriers, 2014-2024 348

Table 131: Sales Forecast ($m) for Bipolar Disorder in the US, 2014-2024 351

Table 132: Key Events Impacting Sales for Bipolar Disorder in the US, 2014-2024 354

Table 133: Bipolar Disorder Market in the US - Drivers and Barriers, 2014-2024 355

Table 134: Sales Forecasts ($m) for Bipolar Disorder in the 5EU, 2014-2024 359

Table 135: Key Events Impacting Sales for Bipolar Disorder in the 5EU, 2014-2024 362

Table 136: Bipolar Disorder Market in the 5EU - Drivers and Barriers, 2014-2024 363

Table 137: Sales Forecasts ($m) for Bipolar Disorder in Japan, 2014-2024 367

Table 138: Key Events Impacting Sales for Bipolar Disorder in Japan, 2014-2024 369

Table 139: Bipolar Disorder Market in Japan - Drivers and Barriers, 2014-2024 370

Table 140: Sales Forecasts ($m) for Bipolar Disorder in Canada, 2014-2024 374

Table 141: Key Events Impacting Sales for Bipolar Disorder in Canada, 2014-2024 376

Table 142: Bipolar Disorder Market in Canada - Drivers and Barriers, 2014-2024 377

Table 143: Key Launch Dates 419

Table 144: Key Patent Expiries 420

Table 145: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country 436

List Of Figures, Charts and Diagrams
in PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024

1.2 List of Figures

Figure 1: The Etiology and Pathophysiology of Bipolar Disorders 34

Figure 2: 8MM, 12-Month Total Prevalent Cases of Bipolar I, Both Sexes, Ages ≥13 Years, 2014-2024 63

Figure 3: 8MM, Bipolar II 12-Month Total Prevalent Cases, Both Sexes, Ages ≥13 Years, 2014-2024 65

Figure 4: 8MM, 12-Month Total Prevalent Cases of Cyclothymic Disorder, Both Sexes, Ages ≥13 Years, 2014-2024 66

Figure 5: 8MM, Age-Specific 12-Month Total Prevalent Cases of Bipolar I, Both Sexes, 2014 70

Figure 6: 8MM, Age-Specific 12-Month Total Prevalent Cases of Bipolar II, Both Sexes, 2014 72

Figure 7: 8MM, Age-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder, Both Sexes, 2014 74

Figure 8: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Bipolar I, Ages ≥13 Years, 2014 76

Figure 9: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Bipolar II, Ages ≥13 Years, 2014 78

Figure 10: 8MM, Sex-Specific 12-Month Total Prevalent Cases of Cyclothymic Disorder, Ages ≥13 Years, 2014 80

Figure 11: 8MM, Age-Standardized 12-Month Total Prevalence of Bipolar Spectrum Disorder, Men, Ages ≥13 Years, 2014 81

Figure 12: 8MM, Age-Standardized 12-Month Total Prevalence of Bipolar Spectrum Disorder, Women, Ages ≥13 Years, 2014 82

Figure 13: The Effects of Lithium on Neurotransmission 129

Figure 14: The Effects of Lithium on Second Messenger Pathways 130

Figure 15: Bipolar Disorder Therapeutics - Class of Therapy, 2016 291

Figure 16: Bipolar Disorder - Phase II-III Pipeline, 2015 293

Figure 17: Clinical and Commercial Positioning of Abilify Maintena 301

Figure 18: Clinical and Commercial Positioning of ITI-007 309

Figure 19: Global Sales of Products for Bipolar Disorder by Company, 2014-2024 316

Figure 20: Company Portfolio Gap Analysis in Bipolar Disorder, 2014-2024 317

Figure 21: Otsuka SWOT Analysis in Bipolar Disorder, 2014-2024 321

Figure 22: AstraZeneca SWOT Analysis in Bipolar Disorder, 2014-2024 324

Figure 23: Eli Lilly SWOT Analysis in Bipolar Disorder, 2014-2024 326

Figure 24: Allergan SWOT Analysis in Bipolar Disorder, 2014-2024 329

Figure 25: Dainippon Sumitomo SWOT Analysis in Bipolar Disorder, 2014-2024 332

Figure 26: Janssen SWOT Analysis in Bipolar Disorder, 2014-2024 335

Figure 27: Lundbeck SWOT Analysis in Bipolar Disorder, 2014-2024 338

Figure 28: Meiji Seika SWOT Analysis in Bipolar Disorder, 2014-2024 340

Figure 29: Global Sales for Bipolar Disorder by Region, 2014-2024 346

Figure 30: Global Sales for Bipolar Disorder by Drug Class, 2014-2024 347

Figure 31: Sales for Bipolar Disorder in the US by Drug Class, 2014-2024 353

Figure 32: Sales for Bipolar Disorder in the 5EU by Drug Class, 2014-2024 361

Figure 33: Sales for Bipolar Disorder in Japan by Drug Class, 2014-2024 368

Figure 34: Sales for Bipolar Disorder in Canada by Drug Class, 2014-2024 375

Additional Details

Publisher

Global Data

Publisher Information

Reference

26558 | GDHC124PIDR

Number of Pages

440

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023
PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023SummaryRenal cel...
21 Apr 2016 by Global Data USD $10,995 More Info
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024SummaryPsoriasis (PsO) is a...
13 Apr 2016 by Global Data USD $10,995 More Info
PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024SummaryBipolar disor...
01 Mar 2016 by Global Data USD $10,995 More Info
PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024...
01 Jan 2016 by Global Data USD $10,995 More Info
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024SummaryDry Eye Syn...
05 Nov 2015 by Global Data USD $10,995 More Info
PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024SummaryAlthough the...
03 Nov 2015 by Global Data USD $10,995 More Info
PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023
PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023SummaryThe Multiple ...
01 Nov 2015 by Global Data USD $10,995 More Info
PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024SummaryIn t...
01 Oct 2015 by Global Data USD $10,995 More Info
PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024SummaryMultiple Sc...
10 Sep 2015 by Global Data USD $10,995 More Info
PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024SummaryAllergic Rhi...
01 Sep 2015 by Global Data USD $10,995 More Info

This report is published by Global Data

Download Free Report Summary PDF

PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data